ClinicalTrials.gg
Enrolling by invitationNCT05796440OraGrowtH211Updated Feb 15, 2024

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)

A Phase 2 interventional study of LUM-201 in Growth Hormone Deficiency, sponsored by Lumos Pharma. Enrolling by invitation at 7 sites in 2 countries. Open to participants aged 5 Years to 14 Years. Per ClinicalTrials.gov, last updated 2024-02-15.

Sponsored by Lumos Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
5 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 89 studies in Dwarfism, Pituitary with a site in United States — 11 open to participants now, 12 under way, 3 of them phase 3. Dwarfism, Pituitary · United States.

Planned enrollment
28th of 66
60 · median 49
Started
2023
with 5 others
Phase 2
15 of 89
3 open now
Primary completion
2028-03
later than 5 of 11 live
Registered
87th of 89
by date
Lead sponsor
4 of 89
Lumos Pharma

Among the 89 studies in Dwarfism, Pituitary with a site in United States, this one is the 28th largest by planned enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2023, is one of 15 in phase 2, reaches primary completion later than 5 of the 11 other live ones, and was the 87th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

11 of the 89 studies in Dwarfism, Pituitary with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 5 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Dwarfism, Pituitary with a site in United States, or all of them as a file.
02

Study summary

This is a multi-national trial. The trial aims to study the long-term safety of LUM-201 in subjects with Idiopathic Pediatric Growth Hormone Deficiency (iPGHD). This study will also assess pharmacodynamics and efficacy response to therapy with LUM-201.

Read the detailed description

An Extension Study to Monitor Long-Term Safety of LUM-201 Treatment in Children with Idiopathic Growth Hormone Deficiency. This study will last for up to 36 months to allow collection of additional long-term safety and efficacy data related to LUM-201 treatment in the pediatric patient population. Subjects will enter into this trial after successful participation in a prior LUM-201 study. This study will consist of visits every 6 months through three years.

There are a total of 7 in-person visits with a follow-up phone call between visits. At the clinic visits, subjects will have a physical exam and blood collection as well as efficacy assessments.

03

Conditions studied

  • Growth Hormone Deficiency

Browse trials for

Keywords

  • LUM-201
  • PGHD
  • GHD
  • Growth hormone secretagogue
  • Oral
  • Height
04

Who can participate

Ages eligible
5 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parent/caregiver must sign the , and the subject must sign the assent, as applicable.
  • Must have successfully participated in a pediatric LUM-201 GHD study through at least the 12-month visit, and be eligible for continuation of treatment, pending all other enrollment criteria are met.

Exclusion criteria

Exclusion Criteria:

  • Medical or genetic condition that, in the opinion of the PI and/or MMs, adds unwarranted risk to the use of LUM-201
  • Has planned or is receiving current long-term treatment with medications known to act as substrates, inducers, or inhibitors of the cytochrome system that metabolizes LUM-201. Subjects receiving shorter-term (two weeks or less) treatment with these medications should be evaluated on case-by-case basis by the PI in consultation with the MMs.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    LUM-201 (1.6 mg/kg/day)

    Drug: LUM-201

Interventions

  • Administered orally once daily

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events

    Number of events

    Time frame: Day 1 to Month 36

Secondary outcomes

  1. Growth Hormone Concentrations in subjects

    Serum GH concentration

    Time frame: Day 1 to Month 36

  2. Insulin-like growth factor 1 concentration

    Serum concentrations of insulin-like growth factor 1

    Time frame: Day 1 to Month 36

  3. Height standard deviation score (SDS)

    Change in HT-SDS

    Time frame: Day 1 to Month 36

  4. Change in Weight SDS

    Change in Weight

    Time frame: Day 1 to Month 36

  5. Annualized Height Velocity (AHV) achieved by daily dosing 1.6mg/kg of LUM-201

    (AHV) measured as standing height with stadiometer

    Time frame: Day 1 to Month 36

  6. Change in Bone Age (BA)

    Change in Bone Age (BA) compared to Chronological Age

    Time frame: Day 1 to Month 36

07

Study locations

7 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for Mar 2028, 55 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2023
First posted
Apr 3, 2023
StartActual
Aug 1, 2023
Primary completionEst.
Mar 2028
CompletionEst.
Apr 2028
Last update
Feb 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05796440
Lead sponsor
Lumos Pharma
Responsible party
Sponsor
First posted
Apr 3, 2023
Start date
Aug 1, 2023
Primary completion
Mar 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Feb 15, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibutamoren

Start the discussion